["Results", "Cloning, Gene\nExpression, and Purification of BlmB and TlmB", "The blmB gene from S. verticillus ATCC15003\nand the tlmB gene from Sa. hindustanus E465-94 ATCC31158 were amplified by PCR, cloned into pET14b to afford\npBS64 and pBS8019, respectively, and transformed into E. coli BL21(DE3) for overexpression. BlmB and TlmB were overproduced as\nN-terminal His6-tagged fusion proteins and purified to\nhomogeneity by Ni-NTA agarose affinity chromatography. The purified\nproteins showed single bands upon SDS\u2013PAGE analysis consistent\nwith the predicted molecular masses of BlmB (34388.8 Da) and TlmB\n(34422.2 Da) (Figure S2 of the Supporting Information).", "BlmB and TlmB Acetylate the Metal-Free Forms of BLM B2, TLM\nA, PLM D1, and ZBM", "As previously reported,22 BlmB is unable to catalyze the acetylation of metal-bound\nBLMs. Incubation of 500 \u03bcM Cu(II)-BLM B2 with 1 mM acetyl-CoA\nand 485 nM BlmB or TlmB showed <4% turnover after 30 min. The addition\nof EDTA led to >80% turnover of BLM B2 under the same conditions\n(Figure\nS3 of the Supporting Information). The\nformation of acetylated BLM B2 was confirmed by HR-MALDI-MS.", "An end point assay utilizing 14C-labeled acetyl-CoA ([acetyl-1-14C]acetyl-CoA), BLM B2 or PLM D1, and\nBlmB further confirmed the metal-free antibiotics as the preferred\nforms of the substrates. Metal-free BLM B2 and Cu(II)-bound BLM B2\nor PLM D1 in the presence of EDTA showed significant turnover compared\nto that of the Cu(II)-bound antibiotic in the absence of EDTA (Figure\nS4 of the Supporting Information).", "Although previous studies reported BlmB did not acetylate bleomycinic\nacid or PLM,21,32 our previous work on isolating\nTLMs30 and ZBM16,31 afforded us the opportunity to examine the substrate flexibility\nof BlmB comparatively with each of the four members of the BLM family.\nBoth BlmB and TlmB were assayed using Cu(II)-BLM B2, TLM A, Cu(II)-PLM\nD1, or Cu(II)-ZBM as a substrate with EDTA included in each reaction\nmixture. After 30 min, the reactions were quenched by boiling, and\nCuSO4 was added to simplify HPLC analysis as the copper-bound\nand metal-free antibiotics elute at different retention times. HPLC\nanalysis of each reaction mixture confirmed that both BlmB and TlmB\nare capable of acetylating BLM B2, TLM A, PLM D1, and ZBM (Figure 2). Each acetylated product was confirmed by HR-MALDI-MS.", "Figure 2BlmB and\nTlmB acetylate four members of the BLM family of antitumor\nantibiotics, BLM B2, TLM A, PLM D1, and ZBM. HPLC analysis of in vitro enzyme reactions: (A) BLM B2 with BlmB, (B) TLM\nA with BlmB, (C) PLM D1 with BlmB, (D) ZBM with BlmB, (E) BLM B2 with\nTlmB, (F) TLM A with TlmB, (G) PLM D1 with TlmB, and (H) ZBM with\nTlmB. Panels A and E (BLM B2), B and F (TLM A), C and G (PLM D1),\nand D and H (ZBM) each show 30 min (I) and 15 min (II), 15 min (I)\nand 5 min (II), 60 min (I) and 30 min (II), and 10 min (I) and 5 min\n(II) reactions, respectively, and enzyme-boiled negative controls\n(III). Highlighted compounds are the antibiotic substrate (\u25cf)\nand acetylated product (*).", "BlmB and\nTlmB acetylate four members of the BLM family of antitumor\nantibiotics, BLM B2, TLM A, PLM D1, and ZBM. HPLC analysis of in vitro enzyme reactions: (A) BLM B2 with BlmB, (B) TLM\nA with BlmB, (C) PLM D1 with BlmB, (D) ZBM with BlmB, (E) BLM B2 with\nTlmB, (F) TLM A with TlmB, (G) PLM D1 with TlmB, and (H) ZBM with\nTlmB. Panels A and E (BLM B2), B and F (TLM A), C and G (PLM D1),\nand D and H (ZBM) each show 30 min (I) and 15 min (II), 15 min (I)\nand 5 min (II), 60 min (I) and 30 min (II), and 10 min (I) and 5 min\n(II) reactions, respectively, and enzyme-boiled negative controls\n(III). Highlighted compounds are the antibiotic substrate (\u25cf)\nand acetylated product (*).", "Kinetic Characterization of BlmB and TlmB Reveals No Substantial\nPreference for Any Member of the BLM Family", "Michaelis\u2013Menten\nkinetic parameters for the four selected members of the BLM family,\neach in its metal-free form, are listed in Table 1. Rates (kcat) and Michaelis constants (KM) were determined\nfrom a nonlinear regression fit of initial velocities versus concentration\n(Figures S5 and S6 of the Supporting Information). For BlmB, the KM for acetyl-CoA was\ndetermined to be 19 \u03bcM, which corresponded well with the previously\nreported value of 12 \u03bcM.22 Previous\nkinetic studies with BlmB showed substrate inhibition at 12 \u03bcM\nBLM A2 at pH >6.0.22 The reported KM value for BLM A2 (at pH 6.0) was 11 \u03bcM,22 correlating well with a previous KM value for BLM A2 of 13 \u03bcM.21 In our hands, BlmB and TlmB showed no substrate inhibition\nat pH 7.5 yet similar KM values of 15\nand 19 \u03bcM, respectively, for BLM B2. In fact, each member of\nthe BLM family had comparable KM values\nfor both BlmB and TlmB. Rates (kcat) for\neach substrate also had similar values, which were comparable with\npreviously reported values using BLM A2,21,22 with only ZBM showing a modest enhancement in rate versus those\nof the other members of the BLM family.", "Kinetic\nParameters for BlmB and TlmB\nwith Four Selected Members of the BLM Family of Antitumor Antibioticsa", "BlmB TlmB.", "BLM\u00a0B2 TLM\u00a0A PLM\u00a0D1 ZBM BLM\u00a0B2 TLM\u00a0A PLM\u00a0D1 ZBM.", "kcat (min\u20131) 12\u00a0\u00b1\u00a02 8.2\u00a0\u00b1\u00a01.7 1.9\u00a0\u00b1\u00a00.5 29\u00a0\u00b1\u00a03 6.2\u00a0\u00b1\u00a00.6 4.4\u00a0\u00b1\u00a00.6 2.2\u00a0\u00b1\u00a00.4 21\u00a0\u00b1\u00a02.", "KM (\u03bcM) 15\u00a0\u00b1\u00a05 45\u00a0\u00b1\u00a017 40\u00a0\u00b1\u00a025 21\u00a0\u00b1\u00a09 19\u00a0\u00b1\u00a05 42\u00a0\u00b1\u00a014 40\u00a0\u00b1\u00a016 25\u00a0\u00b1\u00a06.", "kcat/KM (s\u20131\u00a0M\u20131) 1.3\u00a0\u00d7\u00a0104 3.0\u00a0\u00d7\u00a0103 7.9\u00a0\u00d7\u00a0102 2.3\u00a0\u00d7\u00a0104 5.4\u00a0\u00d7\u00a0103 1.7\u00a0\u00d7\u00a0103 9.2\u00a0\u00d7\u00a0102 1.4\u00a0\u00d7\u00a0104.", "The values are\naverages of at least\ntwo independent assays and are reported with standard errors.", "S. flavoviridis Does Not\nPossess a blmB/tlmB Homologue Outside\nthe Cloned zbm Gene Cluster", "Given the ability\nof BlmB and\nTlmB to efficiently acetylate ZBM in vitro, it is\nsurprising that the cloned zbm gene cluster does\nnot possess a blmB/tlmB homologue.\nTo determine if a blmB/tlmB homologue\nresides outside the cloned zbm gene cluster, we deleted\nthe zbm gene cluster from S. flavoviridis SB9001, a ZBM overproducer derived from the wild-type S.\nflavoviridis ATCC21892 strain,16 to afford recombinant strain S. flavoviridis SB9031;\nthe \u0394zbmA-orf38 genotype of S. flavoviridis SB9031 was confirmed by Southern analysis\n(Figure S7 of the Supporting Information). S. flavoviridis SB9031 is incapable of ZBM production\nand eliminates the only known form of self-resistance to ZBM, the\nZBM-binding protein ZbmA. The susceptibility of S. flavoviridis SB9031 to Cu(II)-ZBM was determined using the disk diffusion assay.\nWhile S. flavoviridis SB9001 showed resistance up\nto 20 \u03bcg of ZBM per disk, the S. flavoviridis SB9031 mutant was sensitive at quantities as low as 0.5\u20131\n\u03bcg of ZBM per disk, excluding the existence of other resistance\nelements on the S. flavoviridis SB9031 genome (Figure 3A).", "Figure 3Disk diffusion assays for Cu(II)-ZBM susceptibility of\nselected S. flavoviridis recombinant strains in comparison\nwith the\nwild-type strain. (A) SB9001 (wild-type) and SB9031 (\u0394zbmA-orf38) challenged with 0, 0.1, 0.5, 1, 5, 10, and 20\n\u03bcg of Cu(II)-ZBM (clockwise from the top right filter, respectively).\n(B) SB9034 (i.e., SB9031/pBS65 expressing blmB under\nits putative native promoter) and SB9035 (i.e., SB9031/pBS66 expressing blmB under the ErmE* promoter) challenged\nwith 0, 0.1, 0.5, 1, 5, 10, and 20 \u03bcg of Cu(II)-ZBM (clockwise\nfrom the top right filter, respectively).", "Disk diffusion assays for Cu(II)-ZBM susceptibility of\nselected S. flavoviridis recombinant strains in comparison\nwith the\nwild-type strain. (A) SB9001 (wild-type) and SB9031 (\u0394zbmA-orf38) challenged with 0, 0.1, 0.5, 1, 5, 10, and 20\n\u03bcg of Cu(II)-ZBM (clockwise from the top right filter, respectively).\n(B) SB9034 (i.e., SB9031/pBS65 expressing blmB under\nits putative native promoter) and SB9035 (i.e., SB9031/pBS66 expressing blmB under the ErmE* promoter) challenged\nwith 0, 0.1, 0.5, 1, 5, 10, and 20 \u03bcg of Cu(II)-ZBM (clockwise\nfrom the top right filter, respectively).", "Expression of blmB Confers ZBM Resistance in S. flavoviridisin Vivo", "To determine\nif BlmB is capable of acetylating ZBM in vivo, as\ndemonstrated in vitro, two blmB expression\nplasmids, pBS65 and pBS66, placing blmB under its\nputative native promoter and the strong promoter ErmE* to ensure its expression in Streptomyces, respectively,\nwere constructed. Introduction of pBS65 and pBS66 into S.\nflavoviridis SB9001 and SB9031, respectively, afforded recombinant\nstrains SB9032, SB9033, SB9034, and SB9035. These strains were assayed\nfor Cu(II)-ZBM susceptibility using the disk diffusion assay with\nthe parent S. flavoviridis SB9001 and SB9031 strains\nas controls. Expression of blmB in SB9031 indeed\nresulted in a significant increase in ZBM resistance. This was evident\nin S. flavoviridis SB9034, which showed resistance\nup to 10 \u03bcg of ZBM per disk, an increase of >10-fold versus\nthat of the parent mutant SB9031. S. flavoviridis SB9035 showed a complete recovery of ZBM resistance as compared\nto the parent wild-type strain SB9001, presumably because of the enhanced\nexpression of blmB under ErmE* (Figure 3B). Similarly, expression of blmB in S. flavoviridis SB9001 also increased the level\nof ZBM resistance; this was more apparent in S. flavoviridis SB9033, where blmB expression was enhanced by ErmE*, than in SB9032 (Figure S8 of the Supporting Information)."]